AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma

TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news